share_log

Allarity Therapeutics | 8-K/A: Current report (Amendment)

Allarity Therapeutics | 8-K/A: Current report (Amendment)

Allarity Therapeutics | 8-K/A：重大事件(修正)
美股SEC公告 ·  09/10 09:18

Moomoo AI 已提取核心訊息

Allarity Therapeutics, Inc. has filed an amendment to its original Form 8-K, correcting the effective time of a reverse stock split to 12:01 a.m. Eastern Time on September 11, 2024. The amendment, filed with the SEC, includes a Certificate of Correction as Exhibit 3.3. Additionally, at the Annual Meeting held on September 3, 2024, stockholders approved several key proposals. These included an increase in the number of shares authorized for grant under the company's 2021 Equity Incentive Plan, amendments to the company's Certificate of Incorporation to decrease the number of authorized shares, and the implementation of a 1-for-30 reverse stock split of the company's common stock. The reverse stock split will result in every 30 shares of issued and outstanding common stock being combined...Show More
Allarity Therapeutics, Inc. has filed an amendment to its original Form 8-K, correcting the effective time of a reverse stock split to 12:01 a.m. Eastern Time on September 11, 2024. The amendment, filed with the SEC, includes a Certificate of Correction as Exhibit 3.3. Additionally, at the Annual Meeting held on September 3, 2024, stockholders approved several key proposals. These included an increase in the number of shares authorized for grant under the company's 2021 Equity Incentive Plan, amendments to the company's Certificate of Incorporation to decrease the number of authorized shares, and the implementation of a 1-for-30 reverse stock split of the company's common stock. The reverse stock split will result in every 30 shares of issued and outstanding common stock being combined into one share, with no fractional shares to be issued. Adjustments will be made to the per share exercise price and the number of shares purchasable upon exercise of outstanding stock options. The common stock will begin trading on a reverse stock split-adjusted basis on the Nasdaq Capital Market on September 11, 2024, under the same trading symbol 'ALLR' and a new CUSIP number.
Allarity Therapeutics, Inc.已就其原始8-k表格提出修正，更正了股票逆向拆股的生效時間爲2024年9月11日東部時間上午12:01。此修正文件已提交給美國證券交易委員會，包括作爲3.3附件的更正證書。此外，在2024年9月3日召開的年度股東大會上，股東批准了幾項關鍵提案。其中包括增加公司2021年股權激勵計劃授權發放股份的數量、修改公司章程以減少授權股份數量，以及實施公司普通股的1比30的逆向拆股。逆向拆股將導致每30股已發行和未流通的普通股合併爲1股，不會發行碎股。將調整每股行使價格以及行使待行權期股權期權時可購買股份的數量。普通股將於2024年9月11日在納斯達克資本市場上以調整後的逆向拆股基礎開始交易，在相同的交易標的『ALLR』和新的CUSIP編號下。
Allarity Therapeutics, Inc.已就其原始8-k表格提出修正，更正了股票逆向拆股的生效時間爲2024年9月11日東部時間上午12:01。此修正文件已提交給美國證券交易委員會，包括作爲3.3附件的更正證書。此外，在2024年9月3日召開的年度股東大會上，股東批准了幾項關鍵提案。其中包括增加公司2021年股權激勵計劃授權發放股份的數量、修改公司章程以減少授權股份數量，以及實施公司普通股的1比30的逆向拆股。逆向拆股將導致每30股已發行和未流通的普通股合併爲1股，不會發行碎股。將調整每股行使價格以及行使待行權期股權期權時可購買股份的數量。普通股將於2024年9月11日在納斯達克資本市場上以調整後的逆向拆股基礎開始交易，在相同的交易標的『ALLR』和新的CUSIP編號下。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間